Alzheimer's disease

The next frontier—Special Report 2017

Jason Karlawish, Clifford R Jr. Jack, Walter A Rocca, Heather M. Snyder, Maria C. Carrillo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging—Alzheimer's Association (NIA-AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis. This Special Report examines how the development and validation of Alzheimer's disease biomarkers—including those detectable in the blood or cerebral spinal fluid, or through neuroimaging—is a top research priority. This has the potential to markedly change how we diagnose Alzheimer's disease and, as a result, how we count the number of people with this disease. As research advances a biomarker-based method for diagnosis and treatment at the earliest stages of Alzheimer's disease, we envision a future in which Alzheimer's disease is placed in the same category as other chronic diseases, such as cardiovascular disease or diabetes, which can be readily identified with biomarkers and treated before irrevocable disability occurs.

Original languageEnglish (US)
Pages (from-to)374-380
Number of pages7
JournalAlzheimer's and Dementia
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Alzheimer Disease
Biomarkers
History of Medicine
Research
Chronic Disease
Cardiovascular Diseases
Guidelines
Delivery of Health Care
Brain

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Alzheimer's disease : The next frontier—Special Report 2017. / Karlawish, Jason; Jack, Clifford R Jr.; Rocca, Walter A; Snyder, Heather M.; Carrillo, Maria C.

In: Alzheimer's and Dementia, Vol. 13, No. 4, 01.04.2017, p. 374-380.

Research output: Contribution to journalArticle

Karlawish, Jason ; Jack, Clifford R Jr. ; Rocca, Walter A ; Snyder, Heather M. ; Carrillo, Maria C. / Alzheimer's disease : The next frontier—Special Report 2017. In: Alzheimer's and Dementia. 2017 ; Vol. 13, No. 4. pp. 374-380.
@article{4895e9ac32ef421687a5c0d250df3d55,
title = "Alzheimer's disease: The next frontier—Special Report 2017",
abstract = "In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging—Alzheimer's Association (NIA-AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis. This Special Report examines how the development and validation of Alzheimer's disease biomarkers—including those detectable in the blood or cerebral spinal fluid, or through neuroimaging—is a top research priority. This has the potential to markedly change how we diagnose Alzheimer's disease and, as a result, how we count the number of people with this disease. As research advances a biomarker-based method for diagnosis and treatment at the earliest stages of Alzheimer's disease, we envision a future in which Alzheimer's disease is placed in the same category as other chronic diseases, such as cardiovascular disease or diabetes, which can be readily identified with biomarkers and treated before irrevocable disability occurs.",
author = "Jason Karlawish and Jack, {Clifford R Jr.} and Rocca, {Walter A} and Snyder, {Heather M.} and Carrillo, {Maria C.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.jalz.2017.02.006",
language = "English (US)",
volume = "13",
pages = "374--380",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Alzheimer's disease

T2 - The next frontier—Special Report 2017

AU - Karlawish, Jason

AU - Jack, Clifford R Jr.

AU - Rocca, Walter A

AU - Snyder, Heather M.

AU - Carrillo, Maria C.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging—Alzheimer's Association (NIA-AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis. This Special Report examines how the development and validation of Alzheimer's disease biomarkers—including those detectable in the blood or cerebral spinal fluid, or through neuroimaging—is a top research priority. This has the potential to markedly change how we diagnose Alzheimer's disease and, as a result, how we count the number of people with this disease. As research advances a biomarker-based method for diagnosis and treatment at the earliest stages of Alzheimer's disease, we envision a future in which Alzheimer's disease is placed in the same category as other chronic diseases, such as cardiovascular disease or diabetes, which can be readily identified with biomarkers and treated before irrevocable disability occurs.

AB - In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging—Alzheimer's Association (NIA-AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis. This Special Report examines how the development and validation of Alzheimer's disease biomarkers—including those detectable in the blood or cerebral spinal fluid, or through neuroimaging—is a top research priority. This has the potential to markedly change how we diagnose Alzheimer's disease and, as a result, how we count the number of people with this disease. As research advances a biomarker-based method for diagnosis and treatment at the earliest stages of Alzheimer's disease, we envision a future in which Alzheimer's disease is placed in the same category as other chronic diseases, such as cardiovascular disease or diabetes, which can be readily identified with biomarkers and treated before irrevocable disability occurs.

UR - http://www.scopus.com/inward/record.url?scp=85017336244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017336244&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2017.02.006

DO - 10.1016/j.jalz.2017.02.006

M3 - Article

VL - 13

SP - 374

EP - 380

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 4

ER -